ישראל - עברית - Ministry of Health

teva israel ltd - terazosin as hydrochloride dihydrate - טבליה - terazosin as hydrochloride dihydrate 5 mg - terazosin

ישראל - עברית - Ministry of Health

novo nordisk ltd., israel - semaglutide - תמיסה להזרקה - semaglutide 0.68 mg / 1 ml - semaglutide

ישראל - עברית - Ministry of Health

novo nordisk ltd., israel - semaglutide - תמיסה להזרקה - semaglutide 1.34 mg / 1 ml - semaglutide

ישראל - עברית - Ministry of Health

novo nordisk ltd., israel - semaglutide - תמיסה להזרקה - semaglutide 1.34 mg / 1 ml - semaglutide

ישראל - עברית - Ministry of Health

novo nordisk ltd., israel - semaglutide - תמיסה להזרקה - semaglutide 2.27 mg / 1 ml - semaglutide

ישראל - עברית - Ministry of Health

novo nordisk ltd., israel - semaglutide - תמיסה להזרקה - semaglutide 3.2 mg / 1 ml - semaglutide

ישראל - עברית - Ministry of Health

abic ltd. - omeprazole - קפסולות - omeprazole 20 mg - omeprazole - omeprazole - acute duodenal ulcer. acute gastric ulcer. helicobacter pylori-associated peptic ulcer disease in combination with antibiotics. reflux esophagitis:- treatment ; - long-term management; - maintenance treatment for the prevention of relapse in patients with severe reflux esophagitis. treatment of severe reflux oesophagitis in children from one year of age and older. - maintenance treatment for the prevention of relapse in patients with poorly responsive peptic ulcer. - zollinger-ellison syndrome. - treatment and prevention of nsaid - associated duodenal and gastric ulcers or erosions in high risk patients.

ישראל - עברית - Ministry of Health

teva israel ltd - clopidogrel as bisulfate - טבליה - clopidogrel as bisulfate 75 mg - clopidogrel - clopidogrel - clopidogrel is indicated for the prevention of atherothrombotic events as follows : * recent mi recent stroke or established peripheral arterial disease : - patients suffering from myocardial infarction (from a few days until less than 35 days ) - ischaemic stroke ( from 7 days until less than 6 months) or established peripheral arterial disease. - for patients with a history of recent myocardial infarction (mi) recent stroke or established peripheral arterial disease - clopidogrel has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not) new mi (fatal or not) and other vascular death. * acute coronary syndrome: - for patients with acute coronary syndrome [non-st segment elevation acute coronary syndrome (unstable angina/non-q-wave mi) or st segment elevation acute myocardial infarction ] in combination with asa in medically treated patients eligible for thrombolytic therapy and those who are to be managed with percutaneous coronary intervention (with or without stent) or

ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - amlodipine as besylate 5 mg; atorvastatin as calcium 10 mg - film coated tablets - amlodipine - caduet (amlodipine and atorvastatin ) is indicated in patients for whom treatment with both amlodipine and atorvastatin is apptopriate. amlodipine: - hypertension - chronic stable angina - vasospastic angina (prinzmetal's or variant angina). atorvastatin : - prevention of cardiovascular disease - heterozygous familial and nonfamilial hypercholesterolemia - elevated serum tg levels - primary dysbetalipoproteinemia - homozygous familial hypercholesterolemia - pediatric patients (10-17 years of age) : atorvastatin is indicated as an adjunct to diet to reduce total -c ldl-c and apo b levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. ldl-c remains >or = 190 mg/dl or 2. ldl-c remains > or = 160 mg/dl and: there is a positive family history of premature cardiovascular disease or two or more other cvd risk factors are present in the pediatric patient.

ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - amlodipine as besylate 5 mg; atorvastatin as calcium 20 mg - film coated tablets - amlodipine - caduet (amlodipine and atorvastatin ) is indicated in patients for whom treatment with both amlodipine and atorvastatin is apptopriate. amlodipine: - hypertension - chronic stable angina - vasospastic angina (prinzmetal's or variant angina). atorvastatin : - prevention of cardiovascular disease - heterozygous familial and nonfamilial hypercholesterolemia - elevated serum tg levels - primary dysbetalipoproteinemia - homozygous familial hypercholesterolemia - pediatric patients (10-17 years of age) : atorvastatin is indicated as an adjunct to diet to reduce total -c ldl-c and apo b levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. ldl-c remains >or = 190 mg/dl or 2. ldl-c remains > or = 160 mg/dl and: there is a positive family history of premature cardiovascular disease or two or more other cvd risk factors are present in the pediatric patient.